Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB)

S. Bacha, S. Merai-Friaa, S. Fazaa, S. Ben Mrad, F. Tritar (Ariana, Tunisia)

Source: Annual Congress 2007 - Epidemiology of tuberculosis II
Session: Epidemiology of tuberculosis II
Session type: Thematic Poster Session
Number: 3824
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Bacha, S. Merai-Friaa, S. Fazaa, S. Ben Mrad, F. Tritar (Ariana, Tunisia). Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB). Eur Respir J 2007; 30: Suppl. 51, 3824

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases – experience from a tuberculosis treatment center in India
Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis
Year: 2009


Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD)
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016



Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity
Source: International Congress 2015 – Screening strategies in TB
Year: 2015

Risk factors of hepatotoxicity during tuberculosis treatment and management
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I
Year: 2008


The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Does the clinical symptoms of drug resistant pulmonary tuberculosis (PTB) act as a predictor in HIV non-infected/infected patient? An Indian scenario
Source: Eur Respir J 2006; 28: Suppl. 50, 858s
Year: 2006

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010



Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016


Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007



Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program
Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban
Year: 2008

Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Does the radiological manifestation of drug resistant pulmonary tuberculosis (PTB) in HIV non-infected/infected patients differ – an Indian picture
Source: Eur Respir J 2007; 30: Suppl. 51, 440s
Year: 2007

Side effects of chemical preparations in patients with drug-resistant pulmonary tuberculosis
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015

HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 654s
Year: 2005

Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Problems in reporting cause of death in patients with tuberculosis (TB)
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007


Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013